<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126024">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01849874</url>
  </required_header>
  <id_info>
    <org_study_id>ARRAY-162-311</org_study_id>
    <secondary_id>2013-000277-72</secondary_id>
    <nct_id>NCT01849874</nct_id>
  </id_info>
  <brief_title>A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Array BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Array BioPharma</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Austria: Federal Office for Safety in Health Care</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>Italy: Italian Medicines Agency</authority>
    <authority>Spain: Spanish Agency of Medicines and Health Products</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Luxembourg: Ministère de la Santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer) is a Phase 3 study during
      which patients with recurrent or persistent low-grade serous (LGS) carcinomas of the ovary,
      fallopian tube or primary peritoneum will receive either investigational study drug MEK162
      or a chemotherapy chosen by the physician (liposomal doxorubicin, paclitaxel or topotecan).
      Patients will be followed to compare the effectiveness of the study drug to that of the
      selected chemotherapies. Approximately 300 patients from North America, Europe and Asia
      Pacific will be enrolled in this study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Demonstrate superior efficacy of study drug vs. physician's choice of selected chemotherapies in terms of increased progression-free survival.</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demonstrate superior efficacy of study drug vs. physician's choice of selected chemotherapies in terms of increased overall survival.</measure>
    <time_frame>6 years post last patient randomized</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obtain additional estimates of the efficacy of study drug vs. physician's choice of selected chemotherapies in terms of objective response rate, duration of response and disease control rate.</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the safety profile of the study drug vs. physician's choice of selected chemotherapies in terms of adverse events and clinical laboratory tests.</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the effect on global health status of study drug vs. physician's choice of selected chemotherapies in terms of quality-of-life questionnaires.</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the plasma pharmacokinetics (PK) of study drug in terms of plasma concentration-time profiles and model-based PK parameters.</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Low-grade Serous Ovarian Cancer</condition>
  <condition>Low-grade Serous Fallopian Tube Cancer</condition>
  <condition>Low-grade Serous Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>MEK162</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Physician's choice chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEK162, MEK inhibitor; oral</intervention_name>
    <description>multiple dose, single schedule</description>
    <arm_group_label>MEK162</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physician's choice chemotherapy</intervention_name>
    <description>Patients will receive one of the following chemotherapies as determined by the physician:
Liposomal doxorubicin, anthracycline antibiotic; intravenous (multiple dose, single schedule)
Paclitaxel, mitotic inhibitor; intravenous (multiple dose, single schedule)
Topotecan, topoisomerase 1 inhibitor; intravenous (multiple dose, single schedule)</description>
    <arm_group_label>Physician's choice chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Diagnosis of LGS carcinoma of the ovary, fallopian tube or primary peritoneum
             (invasive micropapillary serous carcinoma or invasive grade 1 serous carcinoma),
             confirmed histologically and verified by central pathology review.

          -  Recurrent or persistent measurable disease that has progressed (defined as
             radiological and/or clinical progression; an increase in cancer antigen [CA]-125
             alone is not sufficient) on or after last therapy (i.e., chemotherapy, hormonal
             therapy, surgery) and is not amenable to potentially curative intent surgery, as
             determined by the patient's treating physician.

          -  Must have received at least 1 prior platinum-based chemotherapy regimen but have
             received no more than 3 lines of prior chemotherapy regimens, with no limit to the
             number of lines of prior hormonal therapy. Front-line therapy may include neoadjuvant
             and adjuvant therapy and will be counted as 1 prior systemic regimen. Biological
             therapy (e.g. bevacizumab) administered as a single agent is considered a prior
             systemic regimen and not a prior chemotherapy regimen. Maintenance therapy is not
             considered its own regimen but should be included with the regimen that it follows.

          -  Available archival tumor sample (excisional or core biopsy) for confirmation of LGS
             carcinoma diagnosis. If adequate archival tumor sample is not available, willingness
             to consent to tissue biopsy.

          -  Suitable for treatment with at least one of the physician's choice chemotherapy
             options (liposomal doxorubicin, paclitaxel or topotecan) as determined by the
             Investigator.

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.

          -  Additional criteria exist.

        Key Exclusion Criteria:

          -  History or current evidence of retinal vein occlusion (RVO) or current risk factors
             for RVO (e.g., uncontrolled glaucoma or ocular hypertension, history of
             hyperviscosity or hypercoagulability syndromes).

          -  Prior therapy with a MEK or BRAF inhibitor.

          -  History of Gilbert's syndrome.

          -  Impaired cardiovascular function or clinically significant cardiovascular diseases.

          -  Uncontrolled or symptomatic brain metastases that are not stable or require steroids,
             are potentially life-threatening or have required radiation within 28 days prior to
             first dose of study treatment.

          -  Concomitant malignancies or previous malignancies with less than a 5-year
             disease-free interval at the time of first dose of study treatment; patients with
             adequately resected basal or squamous cell carcinoma of the skin, carcinoma in situ
             of the cervix or ductal carcinoma in situ may be enrolled irrespective of the time of
             diagnosis.

          -  Known positive serology for the human immunodeficiency virus (HIV), active hepatitis
             B and/or active hepatitis C.

          -  Prior randomization into this clinical study.

          -  Additional criteria exist.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Array BioPharma Clinical Trial Call Center</last_name>
    <phone>303-381-6604</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelli Williamson</last_name>
      <phone>602-406-6689</phone>
      <email>kelli.williamson@dignityhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deana Garrett, RN</last_name>
      <phone>480-860-5000</phone>
      <phone_ext>244</phone_ext>
      <email>dgarrett@azpoh.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Wallick</last_name>
      <phone>714-456-6191</phone>
      <email>wallicka@uci.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristy Watkins</last_name>
      <phone>323-865-0452</phone>
      <email>kristy.watkins@med.usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Branch</last_name>
      <phone>310-794-3102</phone>
      <email>sbranch@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrina Lopez</last_name>
      <phone>949-642-5165</phone>
      <email>katrinal@gynoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sidney McIntosh</last_name>
      <phone>720-848-0681</phone>
      <email>sidney.mcintosh@ucdenver.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Baker</last_name>
      <phone>203-785-6398</phone>
      <email>lisa.baker@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Sams</last_name>
      <phone>407-303-7354</phone>
      <email>deborah.sams@flhosp.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Tiemann</last_name>
      <phone>813-745-7272</phone>
      <email>jennifer.tiemann@moffitt.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Parks</last_name>
      <phone>773-702-2643</phone>
      <email>tparks@bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Stockman</last_name>
      <phone>319-356-2015</phone>
      <email>sharon-stockman@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jagdish Shetty</last_name>
      <phone>410-328-7680</phone>
      <email>jshetty@umm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Garcia</last_name>
      <phone>313-576-8394</phone>
      <email>garciam@karmanos.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Estkowski</last_name>
      <phone>616-685-5156</phone>
      <email>estkowk@mercyhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynne Lippmann</last_name>
      <phone>314-362-1760</phone>
      <email>lippmannl@wudosis.wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy Miller</last_name>
      <phone>406-435-7482</phone>
      <email>jmiller4@billingsclinic.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheri Westgate</last_name>
      <phone>505-925-0383</phone>
      <email>swestgate@salud.unm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loraine Centrilla</last_name>
      <phone>718-405-8082</phone>
      <email>lcentril@montefiore.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Grisham, MD</last_name>
      <phone>646-888-4653</phone>
      <email>grishamr@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Blakeman</last_name>
      <phone>513-584-5044</phone>
      <email>michael.blakeman@uc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna White</last_name>
      <phone>216-444-3414</phone>
      <email>whited11@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Eaton</last_name>
      <phone>216-844-4710</phone>
      <email>susan.eaton@uhhospitals.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Adairs</last_name>
      <phone>614-293-7582</phone>
      <email>anna.adairs@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Wright, RN</last_name>
      <phone>405-271-8777</phone>
      <email>Deborah-Wright@ouhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Padavic</last_name>
      <phone>215-728-5715</phone>
      <email>kristin.padavic-shaller@fccc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburg</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Kagemann</last_name>
      <phone>412-641-2588</phone>
      <email>kagemannca@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Villalobos, MS</last_name>
      <phone>214-648-7010</phone>
      <email>isabel.villalobos@utsouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Misty Woodall</last_name>
      <phone>713-792-2763</phone>
      <email>mwoodall@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Lothamer</last_name>
      <phone>434-924-9924</phone>
      <email>hll5y@virginia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Western Health</name>
      <address>
        <city>Footscray</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mater Adult Hospital</name>
      <address>
        <city>South Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Burnside War Memorial Hospital</name>
      <address>
        <city>Toorak Gardens</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinic Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l' Ardenne</name>
      <address>
        <city>Libramont</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Ste-Elisabeth</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sint-Augustinus</name>
      <address>
        <city>Wilrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leela Pillay</last_name>
      <phone>403-521-3016</phone>
      <email>leela.pillay@albertahealthservices.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paulo Paralejas</last_name>
      <phone>604-877-6000</phone>
      <phone_ext>3223</phone_ext>
      <email>pparalejas@bccancer.bc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurel Johnston</last_name>
      <phone>204-235-3125</phone>
      <email>laurel.johnston@cancercare.mb.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hal Hirte</last_name>
      <phone>905-387-9495</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Bowering</last_name>
      <phone>416-946-2818</phone>
      <email>valerie.bowering@uhn.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Penny Chipman</last_name>
      <phone>514-398-8307</phone>
      <email>penny.chipman@mcgill.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Grenier</last_name>
      <phone>514-412-7605</phone>
      <email>nathalie.grenier.chum@ssss.gouv.qc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakulni Nemocnice Ostrava</name>
      <address>
        <city>Ostrava-Poruba</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hungarian Defense Forces Medical Centre</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aladar Petz County Teaching Hospital</name>
      <address>
        <city>Gyor</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Josa Andras Oktatokorhaz</name>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Europeo Oncologico</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori di Napoli</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Agostino Gemelli Teaching Hospital</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Emile Mayrisch</name>
      <address>
        <city>Esch-sur-Alzette</city>
        <country>Luxembourg</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosptial Nuestra Senora de Sonsoles</name>
      <address>
        <city>Avila</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosptial Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosptial Universitario Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosptial Universitario Donostia</name>
      <address>
        <city>San Sebastian</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Valencian Institute of Oncology</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research UK</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Luxembourg</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.themilostudy.com/</url>
    <description>TheMILOStudy.com</description>
  </link>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 4, 2014</lastchanged_date>
  <firstreceived_date>May 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
